• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Use of sodium-glucose transport protein 2 inhibitors associated with lowered incidence of gout in patients with type 2 diabetes

byMichael PratteandYuchen Dai
November 23, 2021
in Chronic Disease, Endocrinology, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered incidence of gout compared to dipeptidyl peptidase 4 inhibitors.

2. The benefits of sodium-glucose transport protein 2 inhibitors in achieving a lower gout risk among patients with type 2 diabetes were not significantly different across subgroups.

Evidence Rating Level: 2 (Good)

Study Rundown: The use of sodium-glucose transport protein 2 (SGLT2) inhibitors is currently one of the main classes of therapeutic agents used in patients with type 2 diabetes (T2DM) and has been shown in previous trials to have secondary metabolic effects in lowering blood urate levels. However, the association between SGLT2 inhibitor use and the incidence of gout is not well established. This study retrospectively analyzed patients with T2DM from Taiwan’s National Health Insurance database to assess the association between SGLT2 inhibitor use and the risk of gout incidence compared to dipeptidyl peptidase 4 (DPP4) inhibitor use in this patient population. The main endpoint was a diagnosis of gout based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and the International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Multiple Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95%CIs. Among 47,405 pairs of patients with T2DM, there was a significant risk reduction (11%) in the incidence of gout in patients who received an SGLT2 inhibitor compared with propensity score-matched individuals receiving DPP4 inhibitors, particularly for patients using dapagliflozin. In addition, benefits of SGLT2 inhibitors in achieving a lower gout risk among patients with T2DM were not significantly different across subgroups. These findings suggested that use of SGLT2 inhibitors in patients with T2DM was associated with a lowered gout incidence compared to DPP4 inhibitors. A limitation of this study was that detailed laboratory values such as blood urate levels, crucial to the assessment of gout diagnosis and control, were not included in the database, resulting in a purely clinical association between SGLT2 inhibitors and incidence of gout.

Click to read the study in JAMA Network Open

Relevant Reading: SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

In-Depth [retrospective cohort]: This cohort study included 231,208 patients (113,812 [49.22%] women; mean [SD] age, 61.53 [12.86] years) with T2DM from the Taiwan National Health Institution databases between May 2016 and December 2018, with data analysis completed in June 2021. Among them, 47,905 individuals received SGLT2 inhibitors and 183,303 received DPP4 inhibitors, where 47,405 pairs of patients were included in the 1:1 matched analyses. Overall, the incidence of gout was 20.26 per 1000 patient-years for SGLT2 inhibitor users and 24.30 per 1000 patient-years for DPP4 inhibitor users. After adjusting for potential risk factors in the propensity score-matched population, SGLT2 inhibitor use was associated with a lower risk of gout (HR, 0.89; 95%CI, 0.82- 0.96) compared with DPP4 inhibitors, particularly in patients receiving dapagliflozin (HR, 0.86; 95%CI, 0.78-0.95). This was further confirmed by sensitivity analysis using the ICD-9-CM or ICD-10-CM code for gout-related medication showing a significantly lower risk for gout incidence of 15% with SGLT2 inhibitors (HR, 0.85; 95%CI, 0.74-0.97). Lastly, benefits of SGLT2 inhibitors in achieving a lower gout risk among patients with T2DM were not significantly different across subgroups.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesdiabetes mellitusgoutSGLT-2 inhibitorssglt2 inhibitorstype 2 diabetesType 2 Diabetes Mellitus
Previous Post

Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

Next Post

The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Higher proportions time spent in physical activity decreased all-cause mortality

#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

#VisualAbstract: Physical activity interventions may improve symptoms of attention-deficit/hyperactivity disorder  

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.